RxDoctor Payments Data

Kurt Devito, OD

Optometrist · Virginia Beach, VANPI 1780630863

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $47,229 of the $53,626 with a category attached, or 88.1%. ABB Con-cise Optical Group LLC accounts for 89.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $25,958 and has fallen 59.6% since, to $10,498 in 2025. Among optometrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,626in general payments, 2019–2025

Across 135 payments — averaging $397.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ABB Con-cise Optical Group LLC$48K
  • Coopervision Inc.$3K
  • Bausch & Lomb Americas Inc.$838
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$816
  • Sun Pharmaceutical Industries Inc.$310
  • AbbVie$255
  • plus $349 from 8 others

What the payments were for

  • Consulting fees$47,22988%
  • Speaking & faculty fees$2,0004%
  • Food & beverage$4,3228%
  • Gifts$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,626 in reported general payments places this provider in the 95th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$22,371
Medicare patients
166
Services billed
1,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine33$29,521
Tobramycin-DexamethasoneTobramycin/Dexamethasone87$4,446
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha37$433
Latanoprost54$353
Azithromycin29$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$255$29,52133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →